Editor

Ractigen Therapeutics announces completion of enrolment and first dosing in phase 2 clinical trial of RAG-17 for SOD1-ALS

BioVie announces topline results of phase 2 trial of bezisterim in early Parkinson’s disease

Vivani Medical announces successful dosing of all participants in a phase 1 trial evaluating NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight...

Theriva Biologics announces first patient dosed in phase 2a clinical trial to evaluate more frequent dosing of VCN-01 (zabilugene almadenorepvec) in first-line patients with...

Pacira BioSciences announces publication of positive two-year phase 1 data for PCRX-201 in annals of the rheumatic diseases

Propanc Biopharma announces positive preclinical and early translational data for PRP showing >90% tumour growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma...

RenovoRx announces first commercial clinical use of RenovoCath in sarcoma patient treatment, marking expansion of targeted drug-delivery device to other solid tumours

EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy

ELRIG unveils keynote speakers for Drug Discovery 2026

Ilmac Lausanne 2026 puts the laboratory of the future, AI and biotools centre stage